If you have bipolar disorder and are thinking about pregnancy — or have just found out you’re pregnant — you’re probably already living with a level of worry that most people don’t have to carry into this decision.
The question of what to do about medication during pregnancy is one of the hardest risk-benefit calculations in psychiatric care. There’s no clean answer. Every option carries some combination of risk and uncertainty. And unlike most medical decisions, this one involves two people — and a timeline that doesn’t allow much margin for trial and error.
What you deserve is honest, current information about what the evidence actually shows. Not a simplified “medications are dangerous” narrative. Not false reassurance. The real picture: complicated, nuanced, and genuinely manageable with the right clinical support.
If you’re navigating this question in Illinois, Ohio, or Virginia and want a conversation with a bipolar-specialized clinician, Sway Health works with patients through exactly these kinds of decisions.
At a Glance
- Pregnancy is a high-risk period for bipolar relapse — especially postpartum, which carries among the highest relapse rates of any psychiatric trigger
- In women with a prior bipolar diagnosis, nearly 55% experience at least one mood episode during the perinatal period
- No psychotropic medications are officially FDA-approved for use during pregnancy — but stopping medication carries significant risks of its own
- The risk picture for lithium has been revised significantly downward from 1990s data; valproate remains the highest-risk option and is generally avoided
- Every decision in this area should involve a bipolar-specialized clinician and ideally begin before conception
Why Pregnancy Is a High-Risk Period for Bipolar Disorder
Bipolar disorder tends to have its onset during early adulthood — which means it overlaps almost entirely with reproductive years. This isn’t just statistical bad luck. The overlap creates a genuine clinical challenge: the treatments that keep people stable are exactly the treatments that require careful consideration during pregnancy.
According to a 2022 systematic review and meta-analysis of perinatal bipolar disorder, among women with a prior bipolar diagnosis, 54.9% experienced at least one bipolar-spectrum mood episode during the perinatal period — defined as pregnancy through 12 months postpartum. In women with no previous diagnosis, the screening rate for unrecognized bipolar disorder was 2.6%.
This is not a small number. Pregnancy is not protective against bipolar relapse. In many cases, it’s a trigger for it.
The reasons are multiple: medication discontinuation (often because of worry about fetal exposure), hormonal fluctuations, sleep disruption during late pregnancy and newborn care, and the profound role-transition stress that accompanies becoming or expanding as a parent — all of which are known social rhythm disruptions that the circadian system of a person with bipolar disorder is particularly vulnerable to.
The Postpartum Period: The Highest-Risk Window
If pregnancy itself carries elevated risk, the postpartum period carries even more.
A systematic review of 37 studies covering over 5,700 deliveries found that the overall postpartum relapse risk for women with bipolar disorder was approximately 35%. A separate review of 16 studies with 6,064 deliveries found a postpartum relapse rate of 36.77%.
To put that in clinical context: women with bipolar disorder face a relative risk of postpartum psychiatric hospitalization of 37.2 — compared to 4.6 for schizophrenia and 3.0 for other psychiatric disorders. The period of highest risk of hospitalization is specifically days 10–19 postpartum.
This isn’t postpartum depression as typically described. Bipolar-specific postpartum illness can include full manic or mixed episodes, psychosis, and severe depression — often within days of delivery, and often in a woman who felt completely stable throughout her pregnancy.
The clinical implication of this data is significant: the postpartum period requires a proactive plan, not a reactive one. A clinicians’ guide published in 2025 recommends that every woman with bipolar disorder have a written perinatal plan developed before or early in pregnancy — covering maintenance treatment, immediate postpartum prophylaxis, feeding preferences, sleep preservation strategies, and early warning sign recognition.
The Medication Decision: What the Evidence Actually Shows
The core tension in bipolar disorder and pregnancy is this: no psychotropic medications are officially approved for use during pregnancy in the US. At the same time, stopping medication dramatically increases relapse risk — and untreated bipolar episodes during pregnancy carry their own risks for both the mother and the developing baby.
As the DBSA notes: “None have been proven to be completely safe or free from risk.”
That’s an honest statement. What varies enormously is the degree of risk — and that’s where the clinical nuance matters.
The data on stopping medication entirely is unambiguous: without maintenance therapy, the recurrence rate reaches 71%. With maintenance therapy, it drops to 24%. Stopping abruptly is particularly dangerous — recurrence risk is significantly greater following rapid discontinuation (1-14 days) compared to a slower taper.
Here’s what the current evidence shows for the most commonly used medications:
Lithium
Lithium — Ebstein’s anomaly (a cardiac malformation) has historically been cited as a major risk of first-trimester lithium exposure. The original 1990s data suggested a risk of approximately 1-2%. More recent large cohort studies have revised this substantially downward — the risk is now estimated at 0.05–0.1% of live births, which is still elevated compared to baseline cardiac malformation rates, but significantly lower than previously believed.
More recent reviews confirm that studies now show “either no increased malformations risk or a small increase in risk for cardiac malformations including Ebstein’s anomaly.” Given this reassessment, lithium is increasingly considered the gold standard for treating bipolar disorder in the peripartum period, particularly for women with known lithium response.
Read more about lithium for bipolar disorder and how monitoring is managed.
Valproate (Depakote)
Valproate carries the highest fetal risk of any commonly used bipolar medication. The FDA specifically recommends that pregnant people not take valproate for migraine prevention, and that for bipolar disorder, it should only be prescribed during pregnancy if other medications are not effective or cannot be used.
The risks associated with valproate are significant: neural tube defects, major congenital malformations with rates up to 11% in some studies (more than three times baseline), and neurodevelopmental outcomes including lower IQ, developmental delay, and increased risk of autism spectrum disorder. European countries have largely banned valproate during pregnancy.
For most women with bipolar disorder who are pregnant or planning pregnancy, valproate is generally avoided. Learn more about valproate for bipolar disorder in the broader context of treatment choices.
Lamotrigine (Lamictal)
Lamotrigine has a more favorable safety profile than other anticonvulsants. Data on lamotrigine appears more favorable than other antiepileptics, and it does not carry the same neurodevelopmental risks associated with valproate.
Lamotrigine is particularly relevant for bipolar II and for patients whose primary struggle is with depressive episodes. However, its dosing requires adjustment during pregnancy — pregnancy metabolism changes can significantly alter blood levels, requiring close monitoring and often dose increases.
Learn more about lamotrigine for bipolar depression and how it compares to other mood stabilizers.
Atypical Antipsychotics
Medications like quetiapine (Seroquel), olanzapine (Zyprexa), and aripiprazole (Abilify) are increasingly used during pregnancy, particularly for acute mania or as mood-stabilizing adjuncts. The data suggests they carry lower teratogenic risk than valproate or carbamazepine, though there are metabolic considerations and neonatal adaptation concerns. Current clinical guidance treats them as reasonable options in selected cases.
The APA’s position is clear: psychiatric illness in women is most risky during the reproductive years, and identifying and treating perinatal mood disorders — rather than undertreating them out of excessive caution — is the clinical priority.
The Preconception Conversation: Before Pregnancy If Possible
Most of the clinical guidance in this area emphasizes one thing above all: the best time to address medication questions is before conception, not after.
Pregnancies in women with bipolar disorder are more often unplanned than in the general population — a consequence of the condition itself (impaired decision-making during hypomanic states, hypersexuality, and inconsistent use of contraception). This means that many women face this question with an already-developing pregnancy and a short timeline to make decisions.
When planning is possible, a preconception conversation with a bipolar-specialized clinician allows you to:
- Simplify your medication regimen before pregnancy — reducing polypharmacy reduces fetal exposure overall
- Establish baseline blood levels (particularly for lithium and lamotrigine) that can guide dosing adjustments during pregnancy
- Consider gradual crossover to a lower-risk medication if your current regimen includes valproate or carbamazepine
- Develop a written perinatal plan that your OB, therapist, and any other providers can coordinate around
- Discuss your personal episode history — the frequency, severity, and triggers for your episodes — which directly determines how conservative vs. aggressive the medication approach should be
If you are already pregnant, the same conversation is still worth having as early as possible. The window for risk-benefit planning isn’t closed — it’s just shorter.
Postpartum: Planning Ahead for the Highest-Risk Window
Given what the data shows about postpartum relapse risk, the postpartum period requires as much clinical attention as the pregnancy itself — if not more.
Key elements of postpartum planning for people with bipolar disorder:
Prophylactic treatment immediately after delivery. Current guidance recommends prophylactic medication in the immediate postpartum period for all women with known bipolar disorder — including those who chose to discontinue medication during pregnancy. The immediate postpartum period is when relapse risk is highest, and medication should generally resume as soon as possible after delivery.
Sleep preservation as a protective factor. Sleep disruption is among the most potent triggers for bipolar episodes — and the newborn period is systematically sleep-disruptive. Current clinical guidance explicitly identifies sleep preservation as a critical mitigating factor for postpartum psychiatric decompensation. This means practical planning around who handles nighttime feeding, when sleep shifts occur, and how to protect minimum sleep blocks. It’s a clinical issue, not just a lifestyle preference.
Early warning sign recognition. The window between day 10 and day 19 postpartum represents the period of peak hospitalization risk. Having a clear, written agreement with someone close to you about what the early signs of an episode look like — and what the plan is if those signs appear — can be the difference between early intervention and a full relapse.
Breastfeeding considerations. Mood stabilizer use is not a blanket contraindication to breastfeeding. Lamotrigine and valproate are generally considered compatible with breastfeeding, with appropriate infant monitoring. Lithium requires more careful consideration and monitoring of infant serum levels. The decision should involve your prescribing clinician and should account for how breastfeeding affects your sleep — which in turn affects mood stability.
What Bipolar-Specialized Care Looks Like in This Context
General psychiatry and general obstetrics are both insufficient on their own for managing bipolar disorder during pregnancy. What’s needed is someone who understands the clinical specifics of bipolar — the medication differences between subtypes, the relapse pattern for this particular patient, and the evidence for each medication class — and who can coordinate with obstetric care.
A bipolar-specialized clinician approaches this differently than a general provider:
- They understand that “just stop the medication” is not a safe recommendation for bipolar disorder — unlike for some other conditions where discontinuation during pregnancy is lower-risk
- They can help you weigh your personal relapse history against the fetal risk data in a way that’s specific to you, not generic
- They can help you build the kind of written perinatal plan that the current evidence strongly supports
- They’re familiar with the dosing adjustments that pregnancy requires for medications like lithium and lamotrigine — which change as pregnancy progresses
If you’re in Illinois, Ohio, or Virginia and thinking about pregnancy — or already pregnant — a consultation with a Sway Health clinician is a low-commitment way to start that conversation. You don’t have to have all the answers before you come in.
The clinical bottom line: Bipolar disorder and pregnancy is genuinely complex — and anyone who tells you the answer is simple in either direction isn’t working from the current evidence. Stopping medication carries real relapse risk; continuing it carries medication-specific fetal risks that vary significantly by drug. The goal is an individualized risk-benefit decision made with a clinician who knows your history, understands bipolar disorder at a specialist level, and can plan with you across preconception, pregnancy, and the postpartum period.
The best outcome doesn’t happen by accident — it happens with deliberate, bipolar-informed planning. That planning is available to you.
The information in this article is for educational purposes and does not constitute medical advice. Decisions about medication during pregnancy should be made in partnership with your healthcare team, including a clinician with expertise in bipolar disorder.
